A phase II study of talc poudrage for patients with malignant pleural effusions

Phase 2

• Conditions: malignant pleural effusion

• Registration Number: JPRN-UMIN000014552
• Lead Sponsor: ishichita General Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-07-14
• Study Completion: 2019-08-07
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 7

Inclusion Criteria

Not provided

Exclusion Criteria

1. Hypersensitivity to talc. 2. Hypersensitivity to lidocaine hydrochrolide. 3. Severe infection. 4. Severe hypoxemia despite oxgen therapy. 5. Uncontrolled angina or heart failure. 6. Myocardical infarction within 30 days of consent. 7. Severe bleeding diathesis. INR > 2.0 or platelet <60000/mm3. 8. Severe pleural adhesion. 9. Indication for bilateral pleurodesis. 10. History of pleurodeis of affected side. 11. Preganant or during lactation. Patient who hopes to bear child, or who can not keep contraceptive maneuver. 12. Inappropriate to enter this trial judged by the physician in charge

Study & Design

• Study Type: Interventional
• Study Design: Not specified